SGLT2 (sodium-glucose cotransporter 2) inhibitors interfere with the reabsorption of glucose
and sodium in the early proximal renal tubule, but the magnitude and duration of any …

Many patients with heart failure have an iron‐deficient state, which can limit erythropoiesis in
erythroid precursors and ATP production in cardiomyocytes. Yet, treatment with sodium …

Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of major heart
failure events, an action that is statistically linked to enhanced erythropoiesis, suggesting …

For decades, heart failure with preserved ejection fraction (HFpEF) proved an elusive entity
to treat. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently been shown to …

BACKGROUND: It is not known whether the benefits of sodium-glucose cotransporter 2
inhibitors in heart failure persist after years of therapy. METHODS: In the EMPEROR …

Background: The effects of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on regional
tubular sodium handling is poorly understood in humans but may be important for the cardio …

Both acetazolamide and sodium–glucose cotransporter 2 (SGLT2) inhibitors block sodium
reabsorption in the proximal renal tubule primarily through inhibition of sodium–hydrogen …

Background Prior research suggests clinical effects of glucagon‐like peptide‐1 receptor
agonists (GLP‐1RAs) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) are …

Background Effects of antihyperglycemic therapies on cardiovascular and heart failure (HF)
risks have varied widely across cardiovascular outcome trials (CVOTs), and underlying …

Aim To identify the mediators between canagliflozin and renoprotection in patients with type
2 diabetes at a high risk of end‐stage kidney disease (ESKD). Methods In this post hoc …